A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Peking Union Medical College Hospital
PeriPharm
Centre Oscar Lambret
M.D. Anderson Cancer Center
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Herlev Hospital
University of Virginia
Roswell Park Cancer Institute
University of Virginia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Hospices Civils de Lyon
Mayo Clinic
Thomas Jefferson University
M.D. Anderson Cancer Center
University of Oklahoma
University of Pennsylvania
North Eastern German Society of Gynaecological Oncology
Mayo Clinic
Mario Negri Institute for Pharmacological Research
Gustave Roussy, Cancer Campus, Grand Paris
Roswell Park Cancer Institute
University of California, Irvine
University of Pittsburgh
Stiftung Swiss Tumor Institute
University Medical Center Groningen
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Ente Ospedaliero Ospedali Galliera
University of Washington
Shandong University
SCRI Development Innovations, LLC
University of Washington
University of Alabama at Birmingham
Brown University
Universitaire Ziekenhuizen KU Leuven
Ludwig Institute for Cancer Research
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Cantonal Hospital of St. Gallen
University Health Network, Toronto
City of Hope Medical Center
University Medical Center Groningen
University of Wisconsin, Madison
UConn Health
University of Virginia
Duke University
Hoosier Cancer Research Network